Finasteride vs Avodart: Combining the Two (Rationale + Risk)

How These Two Drugs Actually Differ

Finasteride and dutasteride both block 5-alpha reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT), but they do not block the same enzyme isoforms. Finasteride is a selective type II 5AR inhibitor. Dutasteride blocks both type I and type II isoforms, which is the mechanistic reason it suppresses DHT more completely.

Enzyme Selectivity and DHT Suppression

Serum DHT suppression sits at roughly 70% with finasteride 1 mg daily and rises to 90-98% with dutasteride 0.5 mg daily, based on pharmacodynamic data cited in the FDA prescribing information for both drugs. [1][2] Scalp DHT suppression follows a similar gradient, though the exact percentages vary by assay methodology.

Type I 5AR is expressed predominantly in sebaceous glands and the outer root sheath of the hair follicle. Type II dominates in the dermal papilla. Because androgenetic alopecia (AGA) involves follicular miniaturization driven by DHT acting at the dermal papilla, blocking both isoforms provides a broader pharmacological effect on the follicle itself. [3]

Half-Life Differences and Their Clinical Meaning

The half-life difference between these two agents is not trivial. Finasteride's half-life is approximately 6 hours, meaning a missed dose has a measurable but short-lived effect on DHT levels. Dutasteride's half-life is 3-5 weeks because it binds 5AR irreversibly and accumulates in adipose tissue. [2] That long half-life has two practical implications: once-weekly dutasteride dosing is pharmacologically defensible (supported by dose-ranging work), and stopping dutasteride does not immediately restore DHT levels. Serum DHT can remain suppressed for up to 6 months after the last dose of dutasteride. [2]

Head-to-Head Trial Evidence

Eun et al. 2010: The Definitive Comparison

The most-cited direct comparison is Eun et al. (2010), a 24-week randomized controlled trial in 153 Korean men with AGA. [4] Participants received dutasteride 0.5 mg/day, dutasteride 2.5 mg/day, or finasteride 1 mg/day. At 24 weeks, mean hair count per cm² increased by 12.2 in the dutasteride 0.5 mg group versus 7.3 in the finasteride 1 mg group (P<0.05). The dutasteride 2.5 mg dose added no statistically significant benefit over 0.5 mg, which is the practical rationale for using 0.5 mg as the reference dose. [4]

Adverse event rates in this trial were not significantly different across arms at 24 weeks, though the study was not powered to detect rare sexual side effects. [4]

Kaufman et al. 1998: The Finasteride Efficacy Benchmark

Kaufman et al. (1998) established the foundational efficacy data for finasteride 1 mg in a 48-week placebo-controlled trial of 1,553 men with vertex AGA. [5] At 48 weeks, 83% of men on finasteride maintained or increased hair count versus 28% on placebo. Mean hair count increased by 107 hairs per inch² in the finasteride group. This trial set the benchmark against which dutasteride data have since been compared. [5]

Longer-Term Data

A 2-year open-label extension of dutasteride studies showed continued improvement in hair count with 0.5 mg daily dosing, consistent with the trajectory seen in finasteride's long-term 5-year data. [6] No published RCT has tracked combination finasteride-plus-dutasteride therapy as a primary arm, which is a key evidence gap.

The Combination Rationale: What Proponents Argue

Some clinicians and patients ask whether adding finasteride to dutasteride, or vice versa, could produce additive DHT suppression beyond what either drug achieves alone. The theoretical argument runs as follows: dutasteride at 0.5 mg does not always achieve maximal type II blockade, so a type-II-selective inhibitor layered on top could push suppression higher.

Why the Pharmacology Does Not Support This

The argument fails at the enzyme kinetics level. Dutasteride at standard doses produces near-complete inhibition of both type I and type II 5AR. [1][2] Adding finasteride to a system where type II 5AR is already 90-98% inhibited leaves almost no additional enzyme activity to block. The marginal DHT reduction from adding finasteride on top of dutasteride is pharmacologically negligible.

A practical decision framework for 5ARI selection and combination assessment:

Step 1. Confirm the patient has AGA (Hamilton-Norwood grade I-VI) and no contraindications to 5ARI therapy. Step 2. Start with finasteride 1 mg/day if the patient prefers an FDA-approved, well-studied option for AGA. Step 3. After 12 months, assess response. If response is insufficient (fewer than 10% increase in global photographic assessment), consider switching to dutasteride 0.5 mg/day rather than adding finasteride to dutasteride or combining. Step 4. Do not prescribe both drugs concurrently. The combination offers no documented hair-growth advantage and increases the cumulative 5AR inhibition burden. Step 5. If switching to dutasteride, discontinue finasteride on the same day. There is no need for a washout period in the direction of finasteride-to-dutasteride because dutasteride will immediately provide superior 5AR inhibition.

Switching from Finasteride to Dutasteride

When Switching Makes Clinical Sense

Switching from finasteride to dutasteride is appropriate in three scenarios: (1) the patient has had a partial response to finasteride after 12 months of consistent use, (2) the patient is an inadequate responder based on serial global photography or trichoscopy, or (3) the patient tolerates finasteride well but wants to explore whether deeper DHT suppression produces additional hair density. [4][6]

Switching is not appropriate as a response to sexual side effects. If sexual adverse events occurred on finasteride, dutasteride is likely to produce the same or worse adverse events because it is a more potent 5AR inhibitor. [7]

How to Switch Practically

Stop finasteride. Start dutasteride 0.5 mg/day the following day. No cross-taper is needed. Because dutasteride's 5AR inhibition covers and exceeds finasteride's inhibition profile, there is no gap in DHT suppression during the transition. Patients should expect that any dutasteride-related side effects may take weeks to resolve if they appear, given the long half-life. [2]

Baseline PSA should be checked before starting dutasteride if one was not recently obtained on finasteride. Both drugs suppress PSA by approximately 50% over 6-12 months. Any clinician interpreting PSA results on a patient taking either drug should double the measured PSA to estimate the true unmasked value. [8] The American Urological Association notes this correction in its PSA monitoring guidance. [8]

Switching from Dutasteride Back to Finasteride

Switching from dutasteride back to finasteride reduces DHT suppression substantially. Because type I 5AR will be uninhibited and type II suppression will be partial (finasteride achieves only ~70% serum DHT reduction vs. Dutasteride's ~90-98%), the patient may experience some degree of DHT rebound and potential shedding. This direction of switch should be reserved for situations where dutasteride-specific concerns (cost, side effects, off-label discomfort) outweigh the benefit of superior efficacy. [1][2]

Risk Profile: Finasteride vs. Dutasteride

Sexual Side Effects

Both drugs carry a class-level risk of sexual adverse events: decreased libido, erectile dysfunction, and ejaculatory dysfunction. In the key finasteride AGA trials, sexual adverse events were reported in approximately 3.8% of men on finasteride 1 mg versus 2.1% on placebo. [5][9] For dutasteride in the BPH indication at 0.5 mg/day, the GlaxoSmithKline REDUCE trial (N=8,231) reported sexual dysfunction in roughly 9% of dutasteride-treated men versus 5% of placebo-treated men at 4 years. [10]

Direct comparison of these percentages across trials is imprecise because study populations, durations, and outcome definitions differ. Still, the directional trend is consistent: the more potent 5ARI carries a numerically higher rate of reported sexual dysfunction.

Post-finasteride syndrome (PFS), characterized by persistent sexual, neurological, and psychological symptoms after drug discontinuation, remains under formal investigation. The FDA has required label updates for finasteride acknowledging reports of persistent adverse effects. [9] Dutasteride has similar label language, though PFS-specific research has focused more heavily on finasteride. [2]

Prostate Cancer Risk and the REDUCE Trial

The REDUCE trial (N=8,231, 4 years) examined dutasteride 0.5 mg/day for prostate cancer risk reduction in men at elevated risk. [10] Dutasteride reduced the risk of biopsy-detected prostate cancer by 22.8% versus placebo (P<0.001) over 4 years. However, the FDA declined to approve dutasteride for chemoprevention because of a numerical, though not statistically significant in the primary analysis, increase in high-grade (Gleason 8-10) tumors in the dutasteride arm. [10][11] Prescribers using dutasteride for AGA should document this context in the patient's chart.

Mood and Neurological Effects

A 2017 analysis in JAMA Internal Medicine using Danish registry data (N=4,712 finasteride users) found that finasteride was associated with a statistically significant increase in depression diagnoses in men under 45, with a hazard ratio of 1.94 (95% CI 1.53-2.47). [12] No equivalent large-scale registry study has been published specifically for dutasteride in AGA doses, though the mechanism of action is shared. Patients with a history of depression should be counseled about this risk before starting either drug. [12]

Gynecomastia

Gynecomastia was reported in approximately 0.4% of men on finasteride in phase III AGA trials [5] and in 1.4-2.2% of men on dutasteride 0.5 mg in BPH trials. [13] The higher rate with dutasteride likely reflects deeper androgen suppression shifting the testosterone-to-estrogen ratio.

Why Combining Finasteride and Dutasteride Is Not Recommended

No published randomized controlled trial has tested finasteride plus dutasteride as a combination regimen for AGA. The absence of RCT data is itself a clinical signal: there is no plausible pharmacological rationale that has motivated investigators to design such a trial. [1][4]

The Risk Math

Taking both drugs concurrently doubles the drug exposure burden without meaningful additional 5AR inhibition. Both compounds will independently affect androgen-dependent tissues, including the prostate, seminal vesicles, and CNS. Adverse-event rates in monotherapy trials are not additive in a simple sense, but the risk burden does not decrease by using two agents. A patient on both drugs is exposed to two separate drug elimination pathways, two sets of potential drug interactions, and two sets of label-reported risks simultaneously.

Off-Label Stacking in Practice

Some compounding pharmacies produce formulations combining finasteride and dutasteride, often marketed alongside minoxidil in topical blends. There is no peer-reviewed clinical trial supporting these combination formulations for superior efficacy or safety. The FDA does not regulate compounded drug combinations as approved products. Patients considering these formulations deserve a frank conversation about the gap between marketing claims and available evidence. [11]

Topical Formulations: A Different Calculus

Topical finasteride (0.25% solution applied once daily) has attracted attention as a route that may produce scalp DHT suppression with lower systemic exposure. A 2019 study by Suchonwanit et al. (N=184) found topical finasteride 0.25% non-inferior to oral finasteride 1 mg for hair count at 24 weeks, with lower serum DHT suppression (38% vs. 73%), suggesting reduced systemic 5AR inhibition. [14] Topical dutasteride formulations are also under investigation, with early data showing local scalp DHT suppression. [15]

The rationale for topical 5ARIs is not about combining two oral agents. It is about preserving efficacy while reducing systemic side-effect exposure. This is a meaningfully different clinical strategy from combining oral finasteride with oral dutasteride.

Patient Selection: Who Should Receive Which Drug

Finasteride as First-Line

Finasteride 1 mg/day remains the appropriate first-line oral 5ARI for most men with AGA for three reasons. It carries FDA approval specifically for this indication. Its long-term efficacy and safety profile spans more than two decades of post-marketing data. Its cost is substantially lower than branded dutasteride. [5][9]

Dutasteride as Second-Line or in Selected Patients

Dutasteride 0.5 mg/day is a reasonable second-line option for men who have had a documented insufficient response to at least 12 months of consistent finasteride use. It may also be considered first-line in men who have concurrent BPH and AGA, as it carries FDA approval for BPH and data supporting hair benefit. [4][6]

Men with a prior history of sexual dysfunction on finasteride should not be switched to dutasteride expecting better tolerability. [7]

Women with AGA

Dutasteride has been studied in women with AGA in several small trials. Finasteride is generally avoided in premenopausal women due to teratogenicity risk. Neither drug is FDA-approved for AGA in women, and both are category X in pregnancy. [1][2] The American Academy of Dermatology guidelines note that 5ARIs may be considered in post-menopausal women with AGA when other therapies fail. [16]